《大行》交银国际降翰森制药(03692.HK)目标价至44.5元 去年业绩超预期

阿斯达克财经
Apr 01

交银国际发表报告指,翰森制药(03692.HK) 2025年业绩超预期,2026年创新药销售和BD延续高增长。公司全年收入和净利润按年分别增长23%及27%,各至150.3亿/55.6亿元人民币(下同),均超该行及市场预期。展望2026年,管理层指引产品销售和合作收入均将实现双位数增长,并预计研发投入增幅将超过30%。长期来看,公司预计阿美乐销售在2030年前将保持稳定增长,维持80亿元的销售高峰...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10